Jeffrey A. Bluestone

93.1k total citations · 35 hit papers
499 papers, 69.0k citations indexed

About

Jeffrey A. Bluestone is a scholar working on Immunology, Genetics and Oncology. According to data from OpenAlex, Jeffrey A. Bluestone has authored 499 papers receiving a total of 69.0k indexed citations (citations by other indexed papers that have themselves been cited), including 384 papers in Immunology, 119 papers in Genetics and 113 papers in Oncology. Recurrent topics in Jeffrey A. Bluestone's work include T-cell and B-cell Immunology (299 papers), Immune Cell Function and Interaction (260 papers) and Immunotherapy and Immune Responses (150 papers). Jeffrey A. Bluestone is often cited by papers focused on T-cell and B-cell Immunology (299 papers), Immune Cell Function and Interaction (260 papers) and Immunotherapy and Immune Responses (150 papers). Jeffrey A. Bluestone collaborates with scholars based in United States, France and Australia. Jeffrey A. Bluestone's co-authors include Qizhi Tang, Theresa L. Walunas, Deborah J. Lenschow, Kevan C. Herold, Benoı̂t L. Salomon, Craig B. Thompson, Abul K. Abbas, Mark S. Anderson, Gregory L. Szot and Brian T. Fife and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Jeffrey A. Bluestone

496 papers receiving 67.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD28/B7 SYSTEM OF T CELL COSTIMULATION

1996 2.2k citations Theresa L. Walunas, Jeffrey A. Bluestone et al. profile →
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

2006 2.1k citations Weihong Liu, Amy Putnam et al. The Journal of Experimental Medicine profile →
CTLA-4 can function as a negative regulator of T cell activation

1994 1.8k citations Theresa L. Walunas, Jeffrey A. Bluestone et al. profile →
Innate immunity and intestinal microbiota in the development of Type 1 diabetes

2008 1.5k citations Gregory L. Szot, Jeffrey A. Bluestone et al. profile →
Identification of a monoclonal antibody specific for a murine T3 polypeptide.

1987 1.5k citations Jeffrey A. Bluestone et al. Proceedings of the National Academy of Sciences profile →
The B7 and CD28 receptor families

1994 1.1k citations Jeffrey A. Bluestone et al. profile →
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo

2009 1.0k citations Maki Nakayama, Jeffrey A. Bluestone et al. profile →
Natural versus adaptive regulatory T cells

2003 1.0k citations Jeffrey A. Bluestone, Abul K. Abbas profile →
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes

2004 1.0k citations Qizhi Tang, Gregory L. Szot et al. The Journal of Experimental Medicine profile →
Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg

1992 966 citations J. Richard Thistlethwaite, Jeffrey A. Bluestone et al. Science profile →
Genetics, pathogenesis and clinical interventions in type 1 diabetes

2010 917 citations Jeffrey A. Bluestone, Kevan C. Herold et al. profile →
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

2002 903 citations Kevan C. Herold, Stephen E. Gitelman et al. profile →
Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis

2013 884 citations Jeffrey A. Bluestone et al. profile →
Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation

2001 867 citations Benoı̂t L. Salomon, Jeffrey A. Bluestone profile →
THE NOD MOUSE: A Model of Immune Dysregulation

2004 857 citations Mark S. Anderson, Jeffrey A. Bluestone profile →
Type 1 diabetes immunotherapy using polyclonal regulatory T cells

2015 810 citations Jeffrey A. Bluestone, Stephen E. Gitelman et al. Science Translational Medicine profile →
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation

2008 800 citations Qizhi Tang, Jeffrey A. Bluestone profile →
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

2008 791 citations Brian T. Fife, Jeffrey A. Bluestone profile →
CTLA-4 ligation blocks CD28-dependent T cell activation.

1996 656 citations Theresa L. Walunas, Jeffrey A. Bluestone et al. The Journal of Experimental Medicine profile →
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice

2005 627 citations Qizhi Tang, Brian T. Fife et al. profile →
CD28 Costimulation: From Mechanism to Therapy

2016 623 citations Jonathan H. Esensten, Jeffrey A. Bluestone et al. profile →
Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction

2008 610 citations Qizhi Tang, Eliane Piaggio et al. profile →
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

2009 599 citations Brian T. Fife, Todd N. Eagar et al. profile →
Molecular Basis of T Cell Inactivation by CTLA-4

1998 557 citations Kyung‐Mi Lee, Jeffrey A. Bluestone et al. Science profile →
Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells

2003 546 citations Qizhi Tang, Jeffrey A. Bluestone et al. profile →
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

2015 533 citations Kathrin Schumann, Steven Lin et al. Proceedings of the National Academy of Sciences profile →
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo

2012 519 citations Cédric Louvet, Jeffrey A. Bluestone et al. The Journal of Experimental Medicine profile →
Control of TH17 cells occurs in the small intestine

2011 505 citations Jeffrey A. Bluestone, Kevan C. Herold et al. profile →
Treg cell-based therapies: challenges and perspectives

2019 501 citations Jeffrey A. Bluestone et al. profile →
Revisiting IL-2: Biology and therapeutic prospects

2018 452 citations Abul K. Abbas, Eleonora Trotta et al. Science Immunology profile →
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

2018 412 citations Zoe Quandt, Ana Luisa Perdigoto et al. profile →
Next-generation regulatory T cell therapy

2019 347 citations Jeffrey A. Bluestone, Qizhi Tang et al. profile →
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes

2018 275 citations Jonathan T. Sockolosky, Eleonora Trotta et al. Science profile →
Immunotherapy: Building a bridge to a cure for type 1 diabetes

2021 137 citations Jeffrey A. Bluestone, Kevan C. Herold et al. Science profile →
Opportunities for Treg cell therapy for the treatment of human disease

2023 70 citations Jeffrey A. Bluestone et al. profile →

Peers

Countries citing papers authored by Jeffrey A. Bluestone

Since Specialization

Citations

This map shows the geographic impact of Jeffrey A. Bluestone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Bluestone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Bluestone more than expected).

Fields of papers citing papers by Jeffrey A. Bluestone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Bluestone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Bluestone. The network helps show where Jeffrey A. Bluestone may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Bluestone

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Bluestone. A scholar is included among the top collaborators of Jeffrey A. Bluestone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Bluestone. Jeffrey A. Bluestone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Harnessing regulatory T cells to establish immune tolerance 2024 ·Science Translational Medicine ·Patrick Ho, Ellen Cahir-McFarland, Jason D. Fontenot, Tracey Lodie, Adel Nada, Qizhi Tang, Laurence A. Turka, Jeffrey A. Bluestone	24
2	Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis 2023 ·Journal of the Endocrine Society ·Zoe Quandt, Stephanie Kim, Javier Villanueva‐Meyer, (unknown), Arabella Young, (unknown), Jinoos Yazdany, Gabriela Schmajuk, Stephanie Rush, Elad Ziv, Ana Luisa Perdigoto, Kevan C. Herold, Melissa G. Lechner, Maureen A. Su, James Tyrrell, Jeffrey A. Bluestone, Mark S. Anderson, Umesh Masharani	19
3	Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies 2022 ·Science Translational Medicine ·Daniel B. Goodman, Camillia S. Azimi, (unknown), Alexis Talbot, (unknown), Julie Garcia, Nisarg Patel, Byungjin Hwang, David Lee, (unknown), Vivasvan S. Vykunta, Brian R. Shy, Chun Ye, Justin Eyquem, Alexander Marson, Jeffrey A. Bluestone, Kole T. Roybal	51
4	The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes 2021 ·JCI Insight ·Shen Dong, Kamir J. Hiam-Galvez, Cody T. Mowery, Kevan C. Herold, Stephen E. Gitelman, Jonathan H. Esensten, Weihong Liu, Angela Lares, Ashley Leinbach, Michael Lee, Vinh Nguyen, Stanley Tamaki, Whitney Tamaki, (unknown), Morvarid Mehdizadeh, Amy Putnam, Matthew H. Spitzer, Chun Ye, Qizhi Tang, Jeffrey A. Bluestone	151
5	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis 2020 ·Science Immunology ·James Lee, Sadaf Mehdizadeh, Jennifer Smith, Arabella Young, Ilgiz A. Mufazalov, Cody T. Mowery, Adil Daud, Jeffrey A. Bluestone	198
6	Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes breakdown → 2018 ·Science ·Jonathan T. Sockolosky, Eleonora Trotta, Giulia Parisi, Lora K. Picton, Leon Su, Alan Le, Akanksha Chhabra, Stephanie Silveria, Benson M. George, Chris King, Matthew Tiffany, Kevin M. Jude, Leah V. Sibener, David Baker, Judith A. Shizuru, Antoni Ribas, Jeffrey A. Bluestone, K. Christopher García	275
7	Revealing the specificity of regulatory T cells in murine autoimmune diabetes 2018 ·Proceedings of the National Academy of Sciences ·Allyson L. Spence, Whitney E. Purtha, Janice Tam, Shen Dong, (unknown), Chia‐Hsin Ju, Teague Sterling, Maki Nakayama, William H. Robinson, Jeffrey A. Bluestone, Mark S. Anderson, Qizhi Tang	59
8	Pathological conversion of regulatory T cells is associated with loss of allotolerance 2018 ·Scientific Reports ·Jing Hua, Takenori Inomata, Yihe Chen, William Foulsham, William Stevenson, Tina Shiang, Jeffrey A. Bluestone, Reza Dana	75
9	Generation of knock-in primary human T cells using Cas9 ribonucleoproteins breakdown → 2015 ·Proceedings of the National Academy of Sciences ·Kathrin Schumann, Steven Lin, Eric Boyer, Dimitre R. Simeonov, Meena Subramaniam, Rachel E. Gate, (unknown), Chun Ye, Jeffrey A. Bluestone, Jennifer A. Doudna, Alexander Marson	533
10	The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse 2010 ·Clinical & Experimental Immunology ·Lisl K.M. Shoda, Huub T. C. Kreuwel, Kapil Gadkar, Yanan Zheng, Chan C. Whiting, Mark A. Atkinson, Jeffrey A. Bluestone, Diane Mathis, David Young, Saroja Ramanujan	43
11	IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells 2010 ·The Journal of Experimental Medicine ·Yenkel Grinberg‐Bleyer, Audrey Baeyens, Sylvaine You, Rima Elhage, Gwladys Fourcade, Sylvie Grégoire, Nicolas Cagnard, Wassila Carpentier, Qizhi Tang, Jeffrey A. Bluestone, Lucienne Chatenoud, David Klatzmann, Benoı̂t L. Salomon, Eliane Piaggio	338
12	FK506 causes cellular and functional defects in human natural killer cells 2010 ·Journal of Leukocyte Biology ·Tae-Jin Kim, Nayoung Kim, Hyoung Jin Kang, (unknown), Sung Tae Kim, Hyo Seop Ahn, Jeffrey A. Bluestone, Kyung‐Mi Lee	25
13	Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti-LFA-1 Antibody Efalizumab 2010 ·American Journal of Transplantation ·Andrew M. Posselt, Melena D. Bellin, Mehdi Tavakol, Gregory L. Szot, Lynda Frassetto, Umesh Masharani, Robert K. Kerlan, Lawrence Fong, F. Vincenti, B. J. Hering, Jeffrey A. Bluestone, Peter G. Stock	99
14	Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice 2008 ·Proceedings of the National Academy of Sciences ·Cédric Louvet, Gregory L. Szot, Jiena Lang, Michael R. F. Lee, (unknown), Gideon Bollag, Shirley Zhu, Arthur J. Weiss, Jeffrey A. Bluestone	184
15	Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway 2006 ·The Journal of Experimental Medicine ·Brian T. Fife, Indira Guleria, Melanie Gubbels Bupp, Todd N. Eagar, Qizhi Tang, H Bour, Hideo Yagita∥, Miyuki Azuma, Mohamed H. Sayegh, Jeffrey A. Bluestone	265
16	Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigen 2005 ·The Journal of Experimental Medicine ·Birgit Knoechel, Jens G. Lohr, Estelle Kahn, Jeffrey A. Bluestone, Abul K. Abbas	249
17	Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis 2003 ·Journal of Clinical Investigation ·Wanhong Ding, Stefan Beissert, Liang Deng, (unknown), (unknown), Kristina Seiffert, (unknown), (unknown), George F. Murphy, Jeffrey A. Bluestone, Richard D. Granstein	3
18	Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy 2001 ·Journal of Clinical Investigation ·Andrew D. Wells, Matthew C. Walsh, Jeffrey A. Bluestone, Laurence A. Turka	16
19	INDUCTION, MAINTENANCE, AND REVERSAL OF STREPTOZOTOCIN-INDUCED INSULIN-DEPENDENT DIABETES MELLITUS IN THE JUVENILE CYNOMOLGUS MONKEY (Macaca fascilularis)1 1999 ·Transplantation ·Betty Theriault, J. Richard Thistlethwaite, Matteo Levisetti, Craig L. Wardrip, Gregory L. Szot, David S. Bruce, (unknown), Xiantang Li, Gary S. Gray, Jeffrey A. Bluestone, Philip Padrid	52
20	CTLA-4 blockade enhances t cell responses and exacerbates experimental autoimmune encephalomyelitis 1996 ·The FASEB Journal ·Nitin J. Karandikar, (unknown), Theresa L. Walunas, Jeffrey A. Bluestone, Stephen D. Miller	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact